<DOC>
	<DOCNO>NCT00938912</DOCNO>
	<brief_summary>SP848 open-label study evaluate long-term safety , tolerability , efficacy child epilepsy treat Lacosamide ( LCM ) oral solution ( syrup ) LCM tablet adjunctive therapy .</brief_summary>
	<brief_title>An Open-Label Study Determine Safety , Tolerability , Efficacy Oral Lacosamide Children With Epilepsy</brief_title>
	<detailed_description>SP848 open-label study evaluate long-term safety , tolerability , efficacy child epilepsy treat Lacosamide ( LCM ) oral solution ( syrup ) LCM tablet adjunctive therapy . In addition , study design provide continued availability LCM subject complete SP847 ( NCT00938431 ) study subject discontinue SP847 ( NCT00938431 ) , investigator 's opinion , would benefit long-term administration LCM . SP848 open subject participate LCM pediatric clinical study epilepsy also open 100 subject enrol directly SP848 . Permissible LCM dose SP848 2 , 4 , 6 , 8 , 10 , 12 mg/kg/day ( oral solution [ syrup ] ) correspond tablet dose maximum dose 600 mg/day . Subjects enrol SP848 option remain oral solution formulation LCM switch commercial tablet formulation , feasible</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>All subject SP848 must fulfill follow inclusion criterion : A sign informed consent form obtain parent/legal guardian assent obtain subject , require Subject expect benefit participation , opinion investigator Subject caregiver ( may parent , legal guardian , delegate caregiver ) willing able comply study requirement , include maintain daily seizure diary Subjects participate SP847 LCM pediatric clinical study epilepsy must fulfill follow inclusion criterion : Subject complete SP847 ( subject discontinue SP847 due dose reduction status epilepticus ) treatment uncontrolled partialonset seizure , subject participate LCM pediatric clinical study epilepsy Subjects enroll directly SP848 without previous participation Lacosamide ( LCM ) clinical study must fulfill follow inclusion criterion : Subject ≥4 year ≤17 year age Subject diagnosis epilepsy partialonset seizure Subject observe uncontrolled partialonset seizure adequate course treatment ( opinion investigator ) least 2 Antiepileptic Drugs ( AEDs ) ( concurrently sequentially ) Subject observe least 2 countable seizure 4 week period prior Screening Subject stable dosage regimen 1 3 AEDs Subject acceptable candidate venipuncture Subject receive investigational drug use experimental device addition Lacosamide ( LCM ) Subject meet withdrawal criterion primary study ( SP847 ) ( exception subject discontinue due dose reduction status epilepticus ) , experience ongoing Adverse Event ( AE ) Serious Adverse Event ( SAE ) Subject lifetime history suicide attempt , suicidal ideation past 6 month For subject enroll directly SP848 : Subject ever receive LCM Subject know hypersensitivity component investigational medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lacosamide ( VIMPAT )</keyword>
</DOC>